RadNet (NASDAQ:RDNT) Releases Earnings Results, Misses Expectations By $0.14 EPS

Posted by Brenda Bartman on May 13th, 2026

RadNet (NASDAQ:RDNT – Get Free Report) issued its quarterly earnings results on Monday. The medical research company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14), Briefing.com reports. The company had revenue of $575.63 million during the quarter, compared to analyst estimates of $557.93 million. RadNet had a negative net margin of 0.66% and a positive return on equity of 2.77%. The business’s revenue for the quarter was up 22.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.50) EPS.

Here are the key takeaways from RadNet’s conference call:

Despite an estimated <$strong>13 million revenue and <$strong>9 million adjusted EBITDA weather hit, RadNet reported record Q1 revenue (+22.1% YoY) and adjusted EBITDA (+36.3% YoY) and raised 2026 guidance for imaging center revenue, adjusted EBITDA, and free cash flow.
The Digital Health segment finished Q1 with <$strong>97 million in ARR (up 95% YoY), reaffirmed full‑year Digital Health guidance ($135–$145M revenue; $10–$12M adjusted EBITDA), and cites a commercial funnel >$150M total contract value with $7M of signed ARR pending go‑lives.
Operational technology rollouts are boosting throughput — TechLive reduced MRI exam room closure hours, See‑Mode thyroid ultrasound cut slot times from 30 to 20 minutes across ~300 sites, and clinical AI now covers >70% of studies, supporting advanced imaging growth.
Strategic M&A and partnerships expanded RadNet’s footprint and product set with acquisitions of Radiology Regional (13 centers), Northwest Radiology (6 centers) and Gleamer (AI), plus a 51% JV with Trinity Health Saint Alphonsus (~$30M annual revenues), with integrations and cross‑sell efforts underway.
Financial posture: cash of <$strong>455 million and net debt/adjusted EBITDA ~2.0 after acquisition spending; management expects free cash flow–driven deleveraging, while cautioning Digital Health margins are intentionally compressed this year by investments and recent acquisitions (Q1 may be a trough).

RadNet Trading Down 4.3%

RDNT traded down $2.39 during trading on Wednesday, reaching $53.61. 305,463 shares of the company’s stock were exchanged, compared to its average volume of 832,797. The company’s fifty day moving average price is $59.43 and its 200-day moving average price is $69.32. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.76 and a current ratio of 1.17. RadNet has a fifty-two week low of $50.76 and a fifty-two week high of $85.84. The firm has a market capitalization of $4.20 billion, a PE ratio of -298.46 and a beta of 1.43.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Barclays lowered their price target on shares of RadNet from $86.00 to $70.00 and set an “overweight” rating for the company in a report on Tuesday, April 21st. Jefferies Financial Group reaffirmed a “buy” rating and set a $91.00 target price on shares of RadNet in a report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $88.14.

Read Our Latest Stock Report on RadNet

Insider Buying and Selling

In other RadNet news, insider Alma Gregory Sorensen sold 15,000 shares of RadNet stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $62.15, for a total transaction of $932,250.00. Following the completion of the sale, the insider owned 1,208,923 shares of the company’s stock, valued at approximately $75,134,564.45. The trade was a 1.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.60% of the company’s stock.

Institutional Trading of RadNet

A number of institutional investors have recently bought and sold shares of RDNT. AQR Capital Management LLC grew its holdings in shares of RadNet by 5.4% in the 1st quarter. AQR Capital Management LLC now owns 6,846 shares of the medical research company’s stock valued at $340,000 after buying an additional 350 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of RadNet by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 39,341 shares of the medical research company’s stock valued at $1,956,000 after buying an additional 1,699 shares during the period. Jones Financial Companies Lllp grew its holdings in shares of RadNet by 563.4% in the 1st quarter. Jones Financial Companies Lllp now owns 1,705 shares of the medical research company’s stock valued at $85,000 after buying an additional 1,448 shares during the period. United Services Automobile Association acquired a new position in shares of RadNet in the 1st quarter valued at $216,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of RadNet by 2.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 440,543 shares of the medical research company’s stock valued at $21,904,000 after buying an additional 8,762 shares during the period. Institutional investors and hedge funds own 77.90% of the company’s stock.

About RadNet

(Get Free Report)

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.